Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 months of follow up: An Iranian clinical trial

  • Mohsen Foroughipour Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Sahar Gazeran Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords: Multiple Sclerosis, Magnetic Resonance Imaging, Dimethyl Fumarate

Abstract

Background: Multiple sclerosis (MS) is a neurologic disorder with a considerable global burden. During the last decades, some pharmaceutical treatments have been approved for patients with MS. Dimethyl fumarate (DMF) is one of these drugs which has been reported to have early promising results in recent studies, but the efficacy of this drug in patients with MS is still being studied in different parts of the world. In the present study, we evaluated the effectiveness of DMF therapy on reducing relapses, lesions, and disability in Iranian patients with MS.
Methods: The present single-arm before-after study was approved by the Ethics Committee of Mashhad University of Medical Sciences, Mashhad, Iran [Iranian Registry of Clinical Trial (IRCT) code: IRCT20190121042439N1]. Every patient who was diagnosed with relapsing MS was considered eligible to enroll in the present clinical trial. Before receiving DMF therapy, the baseline liver function tests and complete blood count were obtained from all individuals. Also, a baseline brain magnetic resonance imaging (MRI) was obtained and Expanded Disability Status Scale (EDSS) was documented from all patients. After receiving 240 mg DMF twice daily for 12 months, the laboratory and imaging measurements as well as EDSS were repeated. Furthermore, the total number of relapses within the study period was recorded. Satisfaction with DMF treatment was determined by answering a yes-no question.
Results: A total number of 50 patients enrolled in the study and most of them were female (80%). There was a significant decrease in EDSS score and gadolinium (GD)-enhancing lesions after the study period (P < 0.001 for each). Moreover, the attacks significantly dropped after the study period (P < 0.001) and 86% of patients were satisfied with their treatment.
Conclusion: The findings of this study showed that 240 mg DMF administered twice daily can effectively reduce disability and provide satisfaction within the first year of therapy in patients with MS.

References

1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014; 83(11): 1022-4.
2. Mansouri S, Zayeri F. Global and regional trends of multiple sclerosis disability-adjusted life years rates: A 25-year assessment. Neuroepidemiology 2019; 52(1-2): 17-24.
3. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
4. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098-107.
5. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367(12): 1087-97.
6. Setayeshgar S, Kingwell E, Zhu F, Zhang X, Zhang T, Marrie RA, et al. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: The first five-years. Mult Scler Relat Dis 2018; 25: 57-60.
7. Braune S, Grimm S, van Hovell P, Freudensprung U, Pellegrini F, Hyde R, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: Results from the German NeuroTransData registry. J Neurol 2018; 265(12): 2980-92.
8. Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord 2019; 27: 101-11.
9. Conde S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, et al. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: A French retrospective cohort study. Eur J Neurol 2019; 26(3): 460-7.
10. Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: An Italian, multicenter, real-world study. CNS Drugs 2018; 32(10): 963-70.
11. Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther 2018; 40(12): 2077-87.
12. Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler 2015; 21(1): 57-66.
13. D'Amico E, Zanghi A, Callari G, Borriello G, Gallo A, Graziano G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: An Italian real-word multicenter experience. Ther Adv Neurol Disord 2018; 11: 1756286418796404.
14. Kalincik T, Kubala HE, Horakova D, Izquierdo G, Prat A, Girard M, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry 2019; 90(4): 458-68.
15. Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La GS, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol 2018; 265(8): 1850-9.
16. Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study. Neurology 2018; 91(2): e153-e161.
17. Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, et al. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open 2017; 7(3): e013430.
18. Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord 2016; 9: 23-30.
19. Lebrun C, Rocher F. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. CNS Drugs 2018; 32(10): 939-49.
20. Koulinska I, Riester K, Chalkias S, Edwards MR. Effect of bismuth subsalicylate on gastrointestinal tolerability in healthy volunteers receiving oral delayed-release dimethyl fumarate: PREVENT, a randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2018; 40(12): 2021-30.
21. Ochi H, Niino M, Onizuka Y, Hiramatsu K, Hase M, Yun J, et al. 72-week safety and tolerability of dimethyl fumarate in japanese patients with relapsing-remitting multiple sclerosis: Analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther 2018; 35(10): 1598-611.
22. Saida T, Yamamura T, Kondo T, Yun J, Yang M, Li J, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol 2019; 19(1): 5.
Published
2019-08-22
How to Cite
1.
Foroughipour M, Gazeran S. Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 months of follow up: An Iranian clinical trial. Curr J Neurol. 18(4):154-158.
Section
Original Article(s)